Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital

Biomed Res Int. 2020 Nov 6:2020:9126148. doi: 10.1155/2020/9126148. eCollection 2020.

Abstract

Background: Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission. Subjects and Methods. We performed a retrospective study at the Lausanne University Hospital with patients admitted because of COVID-19 from February 28 to April 30, 2020.

Results: Among 443 patients with COVID-19, VTE was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27 (65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value > 3,120 ng/ml (P < 0.001; OR 15.8, 95% CI 4.7-52.9) and duration of 8 days or more from COVID-19 symptoms onset to presentation (P 0.020; OR 4.8, 95% CI 1.3-18.3) to be independently associated with VTE upon admission. D-dimer value ≥ 3,000 ng/l combined with a Wells score for PE ≥ 2 was highly specific (sensitivity 57.1%, specificity 91.6%) in detecting VTE upon admission. Development of VTE during hospitalization was independently associated with D-dimer value > 5,611 ng/ml (P < 0.001; OR 6.3, 95% CI 2.4-16.2) and mechanical ventilation (P < 0.001; OR 5.9, 95% CI 2.3-15.1).

Conclusions: VTE seems to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of Wells ≥ 2 score and D - dimer ≥ 3,000 ng/l is a good predictor of VTE at admission.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antifibrinolytic Agents / therapeutic use
  • COVID-19 / blood*
  • COVID-19 / epidemiology
  • COVID-19 / pathology
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pulmonary Embolism / drug therapy
  • Pulmonary Embolism / epidemiology
  • Pulmonary Embolism / virology
  • Retrospective Studies
  • SARS-CoV-2 / isolation & purification
  • Switzerland / epidemiology
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / epidemiology
  • Venous Thromboembolism / prevention & control
  • Venous Thromboembolism / virology*
  • Venous Thrombosis / drug therapy
  • Venous Thrombosis / epidemiology
  • Venous Thrombosis / prevention & control
  • Venous Thrombosis / virology

Substances

  • Antifibrinolytic Agents
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D